PA
PARD.US Poniard Pharmaceuticals Inc
- Market cap
- USD 149.00
- P/E
- -
- P/B
- 0.10x
- ROE
- -465.2%
- Dividend yield
- 128,859.06%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2011.
Is PARD.US undervalued?
Graham numberThe Graham number of Poniard Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Poniard Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Poniard Pharmaceuticals Inc yet.
Poniard Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Poniard Pharmaceuticals Inc
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase I…
Full company profilePoniard Pharmaceuticals Inc financial statements
2011 annualized: Fiscal year 2011 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2011, the balance sheet is the latest quarter. Figures change when the annual report is published.
Poniard Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.87M | 11.1M | 10.5M | 1.02M | 15.0K | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.87M | 11.1M | 10.5M | 1.02M | 15.0K | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -26.1M | -23.8M | -4.69M | -19.5M | -21.1M | -21.2M | -35.4M | -49.2M | -43.0M | -28.0M | -14.4M |
| EBITDA | -24.8M | -20.9M | -3.89M | -18.7M | -15.5M | -17.0M | -29.9M | -47.6M | -39.0M | -25.0M | -13.2M |
| Net Income | -23.8M | -23.1M | -5.06M | -19.4M | -21.0M | -23.3M | -32.8M | -48.6M | -45.7M | -30.1M | -14.5M |
| EPS | -216 | -208 | -44 | -154 | -150 | -54 | -43 | -56 | -52 | -26 | -9.68 |
| Balance Sheet | |||||||||||
| Total Assets | 51.0M | 26.0M | 35.7M | 27.4M | 10.1M | 69.1M | 105M | 84.2M | 52.4M | 11.6M | 7.74M |
| Total Liabilities | 9.31M | 8.42M | 6.20M | 6.61M | 6.94M | 22.2M | 16.0M | 36.6M | 28.8M | 3.19M | 4.62M |
| Shareholders' Equity | 41.7M | 17.6M | 29.5M | 20.8M | 3.17M | 46.9M | 89.1M | 47.6M | 23.6M | 8.45M | 3.12M |
| Cash & Short-term Investments | 33.6M | 16.1M | 27.5M | 17.8M | 3.52M | 53.7M | 92.6M | 72.8M | 43.4M | 4.33M | 1.98M |
| Total Debt | 6.00M | 5.69M | 4.50M | 4.21M | 3.87M | 13.9M | 10.8M | 25.4M | 20.3M | 1.57M | 1.64M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.5M | -15.4M | -4.07M | -17.5M | -16.5M | -17.3M | -24.7M | -33.5M | -35.5M | -24.3M | -7.21M |
| Capital Expenditure | 7.27M | 682K | 365K | 1.33M | 84.0K | 5.39M | 5.77M | 391K | 21.0K | 7.00K | 24.0K |
| Free Cash Flow | -25.8M | -16.1M | -4.43M | -18.8M | -16.6M | -22.7M | -30.4M | -33.9M | -35.5M | -24.3M | -7.23M |
| Ratios | |||||||||||
| ROE | -57.1% | -131.4% | -17.2% | -93.0% | -661.7% | -49.7% | -36.8% | -101.9% | -193.3% | -355.5% | -465.2% |
| ROA | -46.6% | -88.8% | -14.2% | -70.6% | -207.6% | -33.7% | -31.2% | -57.7% | -87.2% | -258.1% | -187.4% |
| Net Profit Margin | -828.5% | -208.9% | -48.0% | -1,908.5% | -139,980.0% | - | - | - | - | - | - |
| Debt to Equity | 0.14x | 0.32x | 0.15x | 0.20x | 1.22x | 0.30x | 0.12x | 0.53x | 0.86x | 0.19x | 0.53x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Poniard Pharmaceuticals Inc dividends
- Dividend yield
- 128,859.06%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2010 | USD 192K | 0.16 | - |
| 2009 | USD 500K | 0.57 | - |
| 2008 | USD 500K | 0.58 | - |
| 2007 | USD 500K | 0.65 | - |
| 2006 | USD 500K | 1.15 | - |
| 2005 | USD 500K | 3.56 | - |
| 2004 | USD 500K | 3.98 | - |
| 2003 | USD 500K | 4.32 | - |
| 2002 | USD 500K | 4.50 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:40 on Nov 23, 2011.
Who owns Poniard Pharmaceuticals Inc
Ownership data of Poniard Pharmaceuticals Inc is not available yet.
Poniard Pharmaceuticals Inc company profile
- Company name
- Poniard Pharmaceuticals Inc
- Ticker
- PARD.US
- Exchange
- USA Stocks
- Listed since
- Aug 11, 1988
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- 300 Elliott Avenue West, Seattle, WA, United States, 98119
- Phone
- 206 281 7001
- Website
- poniard.com
About Poniard Pharmaceuticals Inc
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Poniard Pharmaceuticals Inc management
2- Dr. Robert F. CaspariExec. Officer · born 1947
- Dr. Paul G. AbramsExec. Officer